BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the most prevalent malignancies and currently shows a poor clinical prognosis. Type II pneumocyte, as one of the main sources of cancer cells in NSCLC, is important to explore the molecular fun...
BACKGROUND: Breast cancer prognosis remains challenging due to tumor heterogeneity and the limited predictive power of conventional clinical models. Integrating imaging features with molecular data may improve individualized risk stratification and c...
BACKGROUND: Cell-free DNA is a promising source of biomarkers for early cancer detection and carries tumor-driven methylation and fragmentation features that have achieved good diagnostic efficacy across various cancers. However, there were no studie...
Precision oncology enables molecularly guided cancer therapy through multi-omics profiling, AI-driven classification, and biomarker-targeted interventions. Disulfidptosis has emerged as a promising therapeutic target, yet no ovarian cancer classifica...
Epithelial ovarian cancer (EOC) is a lethal gynecological malignancy. Ongoing research aimed to identify novel biomarkers and develop combined algorithms to improve diagnosis and prognosis prediction for EOC. RNA-seq related to EOC were obtained from...
The high heterogeneity of colorectal cancer (CRC) complicates accurate prognosis prediction. Hypoxia can affect cell death mechanisms, leading to resistance to many antitumor therapies and potentially causing relapse. Programmed cell death (PCD) form...
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC). Although we have made many achievements in the therapy of RCC with the progress of medicine, the clinical management of metastatic RCC remains a dauntin...
Precision oncology relies on predictive biomarkers for selecting targeted cancer therapies. Network-based properties of proteins, together with structural features such as intrinsic disorder, are likely to shape their potential as biomarkers. We ther...
Although it is the most common subtype of lung cancer in clinical practice, lung adenocarcinoma (LUAD) was proven to be associated with a poor prognosis. In recent years, lactate metabolism has been considered an important biological mechanism in lun...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.